The U.S. Food and Drug Administration approved zenocutuzumab as a second-line therapy for NRG1-positive cholangiocarcinoma on May 8. According to results from the eNRGy phase 2 clinical trial published in the Journal of Clinical Oncology, the drug more than doubled the median progression-free survival to 9.2 months, compared to the approximately four months typically seen with standard chemotherapy.
Why is zenocutuzumab significant for bile duct cancer?
Zenocutuzumab functions as a bispecific antibody. It targets human epidermal growth factor receptor (HER) 2 and 3 to block the signaling driven by Neuregulin 1 (NRG1) gene fusions, which fuels tumor growth. For patients with advanced NRG1-positive cholangiocarcinoma, this offers a precision alternative to traditional chemotherapy.
James Cleary, MD, PhD, a gastrointestinal oncologist at Dana-Farber who led the trial, stated that second-line chemotherapy is only modestly effective for most patients. Cleary noted that zenocutuzumab doubles the duration of clinical benefit and is well tolerated, representing a significant step forward in quality of life.
How does zenocutuzumab compare to standard care?
The eNRGy trial data highlights a stark contrast between targeted therapy and standard second-line chemotherapy. According to the study, only five percent of patients respond radiologically to standard second-line chemotherapy. In contrast, the zenocutuzumab trial reported an objective radiological response rate of 36.8% among the 19 evaluable patients.
| Metric | Standard 2nd-Line Chemotherapy | Zenocutuzumab (eNRGy Trial) |
|---|---|---|
| Median Progression-Free Survival | ~4 Months | 9.2 Months |
| Objective Radiological Response | five percent | 36.8% |
The trial also found that 57.9% of patients experienced clinical benefit. Side effects were reported as low-grade and manageable, primarily consisting of infusion reactions or diarrhea.
What is the role of RNA testing in detecting NRG1 fusions?
Standard DNA-based next-generation sequencing (NGS) often misses NRG1 fusions because the mutations are complex. The eNRGy trial demonstrated that RNA-based NGS is more effective for detection. All but one patient in the cholangiocarcinoma cohort had their fusion confirmed via RNA testing.
Dr. Cleary emphasized the necessity of utilizing both RNA and DNA testing for patients. He expressed concern that patients might miss opportunities to benefit from precision medicines if the correct diagnostic tests aren’t ordered.
What other cancers can be treated with this therapy?
Zenocutuzumab is not limited to cholangiocarcinoma. The drug is also approved for the treatment of:
- Advanced NRG1-positive non-small cell lung cancer.
- KRAS wild-type NRG1-positive pancreatic cancer.
This multi-indication approval underscores a broader trend in oncology toward biomarker-driven treatments, where the genetic mutation of the tumor is more important than the organ where the cancer originated.
Frequently Asked Questions
Who is eligible for zenocutuzumab?
Patients with NRG1-positive cholangiocarcinoma who have progressed after initial chemotherapy or are unsuitable for standard therapy may be eligible.
Is it a first-line treatment?
No. The FDA approved zenocutuzumab specifically as a second-line therapy for NRG1-positive cholangiocarcinoma.
How is the NRG1 fusion detected?
It is detected through molecular profiling. While DNA sequencing is common, RNA-based next-generation sequencing is more likely to identify these specific complex fusions.
Want to stay updated on the latest breakthroughs in precision medicine? Subscribe to our newsletter or leave a comment below to let us know which cancer research topics you want us to cover next.
